You are here

CAR-T

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Fierce Biotech

clinical trials

Multiple Myeloma

Flag link:

Novartis partners with French CDMO to bolster CAR-T supply

Novartis partners with French CDMO to bolster CAR-T supply

Biopharma Dive

Flag link:

Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales

Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales

Fierce Pharma

Gilead Sciences

Flag link:

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

Endpoints

Flag link:

Mustang opens CAR-T manufacturing plant, with focus on lead candidates

Mustang opens CAR-T manufacturing plant, with focus on lead candidates

Biopharma Dive

drug manufacturing

Flag link:

Ziopharm gets hit with a clinical hold as FDA red lights human study using their fast-built CAR-T

Ziopharm gets hit with a clinical hold as FDA red lights human study using their fast-built CAR-T

Endpoints

Flag link:

Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies

Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies

Med City News

bispecific antibodies

Flag link:

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Fierce Biotech

cytokine release syndrome

Flag link:

ASCO18: Celgene makes its case as CAR-T rival in lymphoma

ASCO18: Celgene makes its case as CAR-T rival in lymphoma

Biopharma Dive

B-cell non-Hodgkin lymphoma

Flag link:

Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet

Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet

Forbes

Multiple Myeloma

Flag link:

J&J hustles Legend’s promising BCMA CAR-T into PhI/II trial, winning an FDA green light to begin recruiting patients

J&J hustles Legend’s promising BCMA CAR-T into PhI/II trial, winning an FDA green light to begin recruiting patients

Endpoints

Multiple Myeloma

Flag link:

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Common Serious Side-Effect Of CAR T-Cell Therapy May Be Preventable

Forbes

cytokine release syndrome

Flag link:

Bluebird widens hunt for TCR therapies in revised Medigene deal

Bluebird widens hunt for TCR therapies in revised Medigene deal

Biopharma Dive

Flag link:

Autolus seeks $100M IPO to take next-gen CAR-Ts deep into the clinic

Autolus seeks $100M IPO to take next-gen CAR-Ts deep into the clinic

Fierce Biotech

clinical trials

Flag link:

Researchers at Thomas Jefferson University Eliminate Metastatic Colorectal Cancer in Mice With CAR-T Immunotherapy

Researchers at Thomas Jefferson University Eliminate Metastatic Colorectal Cancer in Mice With CAR-T Immunotherapy

CP Wire

colorectal cancer

Flag link:

Pfizer signs deal with Allogene to develop cancer cell therapy

Pfizer signs deal with Allogene to develop cancer cell therapy

Yahoo/Reuters

drug development

Flag link:

Celgene, bluebird revise deal to co-develop CAR-T therapy

Celgene, bluebird revise deal to co-develop CAR-T therapy

Biopharma Dive

drug development

Multiple Myeloma

Flag link:

Treatment Debates Won’t Slow Down Biotechs

Treatment Debates Won’t Slow Down Biotechs

Barron's

Gilead Sciences

Juno Therapeutics

Flag link:

Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost

Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost

Xconomy

Gilead Sciences

Flag link:

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

BioWorld

Gilead Sciences

Flag link:

Pages